Ani Pharmaceuticals (ANIP) EV to CFO (2013 - 2026)

Ani Pharmaceuticals has disclosed EV to CFO across 14 years of filings, most recently posting 28.49 for Q2 2026.

• In Q2 2026, EV to CFO rose 74.35% year-over-year to 28.49; the TTM figure through Jun 2026 stood at 8.52 (down 4.29% YoY), while the FY2025 annual figure was 8.04, down 49.62% from the prior year.
• EV to CFO came in at 28.49 for Q2 2026 at Ani Pharmaceuticals, up from 25.97 in the prior quarter.
• In the past five years, EV to CFO ranged from a high of 138.33 in Q3 2022 to a low of 147.91 in Q4 2022.
• Average EV to CFO over 5 years is 30.34, with a median of 34.79 recorded in 2023.
• The largest YoY upside for EV to CFO was 285.47% in 2022 against a maximum downside of 279.32% in 2022.
• Over 5 years, EV to CFO stood at 147.91 in 2022, then soared by 113.93% to 20.61 in 2023, then soared by 212.68% to 64.44 in 2024, then dropped by 23.86% to 49.06 in 2025, then tumbled by 41.94% to 28.49 in 2026.
• Per Business Quant data, the three most recent EV to CFO figures were 28.49 in Q2 2026, 25.97 in Q1 2026, and 49.06 in Q4 2025.